← Back to headlines
Biogen Acquires Apellis for $5.6 Billion in Rare Disease Expansion
Biogen is making a strategic move into the rare disease market with a $5.6 billion acquisition of Apellis Pharmaceuticals, aiming to expand its portfolio in this specialized area.
31 Mar, 15:15 — 31 Mar, 15:15
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Farmers' Group Criticizes Proposed Pax Silica Economic Zone in Philippines
just now
Philippine President Marcos Orders P17.27 Billion for Classroom Construction
just now
Philippine President Marcos Pushes P46.22 Billion for Infrastructure Projects
just now